CD45抗体药物偶联物预处理范可尼贫血小鼠实现异基因植入且无显著毒性或GVHD
在3种代表90%范可尼贫血互补群的FA小鼠模型中,单剂抗小鼠CD45抗体药物偶联物(CD45-ADC)促进稳定的多系嵌合。Fanca-/-受体外周血平均供者嵌合>90%,Fancc-/-和Fancg-/-全异基因移植受体分别为60%~80%和70%~80%,无临床毒性。在GVHD移植条件下,CD45-ADC组GVHD致死率较致死性照射明显降低。
要点
- 单剂CD45-ADC在3种FA小鼠模型中实现稳定的多系供者嵌合。
- Fanca-/-受体外周血平均供者嵌合>90%,Fancc-/-和Fancg-/-分别为60%~80%和70%~80%。
- CD45-ADC预处理小鼠无临床毒性,GVHD致死率较致死性照射明显降低。
核心结论
- CD45-ADC可有效促进供者异基因植入和造血,且无显著毒性或严重GVHD,为高危FA患者的临床试验考虑提供有力支持。
研究设计与样本
- 研究在3种代表90%范可尼贫血互补群的FA小鼠模型中进行,并纳入野生型小鼠、Fanca-/-小鼠及恒河猴非人灵长类。
主要发现
- 单剂抗小鼠CD45-ADC在48小时内深度清除宿主Lineage-Sca1+cKit+细胞。
- Fanca-/-受体接受次要错配骨髓和单剂CD45-ADC后,外周血平均供者嵌合>90%,并在二次受体中验证供者HSC植入。
- Fancc-/-和Fancg-/-全异基因移植受体外周血平均供者嵌合分别为60%~80%和70%~80%,骨髓和脾脏平均供者嵌合与外周血结果一致。
- CD45-ADC预处理小鼠无临床毒性,可见一过性肝细胞酶<2.5倍升高和轻至中度组织病理学改变。
- 在GVHD异基因HSCT条件下,野生型和Fanca-/-受体接受CD45-ADC的GVHD致死率较致死性照射明显降低。
临床怎么用
- 原文结论认为CD45-ADC可为高危FA患者的临床试验考虑提供有力支持。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Fanconi anemia (FA) is an inherited DNA repair disorder characterized by bone marrow (BM) failure, developmental abnormalities, myelodysplasia, leukemia, and solid tumor predisposition. Allogeneic hematopoietic stem cell transplantation (allo-HSCT), a mainstay treatment, is limited by conditioning regimen-related toxicity and graft-versus-host disease (GVHD). Antibody-drug conjugates (ADCs) targeting hematopoietic stem cells (HSCs) can open marrow niches permitting donor stem cell alloengraftment. Here, we report that single dose anti-mouse CD45-targeted ADC (CD45-ADC) facilitated stable, multilineage chimerism in 3 distinct FA mouse models representing 90% of FA complementation groups. CD45-ADC profoundly depleted host stem cell enriched Lineage-Sca1+cKit+ cells within 48 hours. Fanca-/- recipients of minor-mismatched BM and single dose CD45-ADC had peripheral blood (PB) mean donor chimerism >90%; donor HSCs alloengraftment was verified in secondary recipients. In Fancc-/- and Fancg-/- recipients of fully allogeneic grafts, PB mean donor chimerism was 60% to 80% and 70% to 80%, respectively. The mean percent donor chimerism in BM and spleen mirrored PB results. CD45-ADC-conditioned mice did not have clinical toxicity. A transient <2.5-fold increase in hepatocellular enzymes and mild-to-moderate histopathological changes were seen. Under GVHD allo-HSCT conditions, wild-type and Fanca-/- recipients of CD45-ADC had markedly reduced GVHD lethality compared with lethal irradiation. Moreover, single dose anti-human CD45-ADC given to rhesus macaque nonhuman primates on days -6 or -10 was at least as myeloablative as lethal irradiation. These data suggest that CD45-ADC can potently promote donor alloengraftment and hematopoiesis without significant toxicity or severe GVHD, as seen with lethal irradiation, providing strong support for clinical trial considerations in highly vulnerable patients with FA.
引用
- Saha A, Palchaudhuri R, Lanieri L, et al. Alloengraftment without significant toxicity or GVHD in CD45 antibody-drug conjugate-conditioned Fanconi anemia mice. Blood. 2024. PMID: 38447038. doi:10.1182/blood.2023023549
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。